Acadia Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
18.75
+0.61 (3.36%)
At close: Nov 13, 2026, 4:00 PM EST
18.75
0.00 (0.00%)
Pre-market: Nov 16, 2026, 4:30 AM EST

Acadia Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Acadia Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $30.32. The average 1-year stock price forecast is 61.71% higher than the current stock price, while the lowest is $16 (-14.67%) and the highest is $38 (+102.67%).

Price Target: $30.32 (+61.71%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$16$30.32$33$38
Change-14.67%+61.71%+76.00%+102.67%

Analyst Ratings

The average analyst rating for Acadia Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy121212111010
Buy444444
Hold444455
Sell000000
Strong Sell111111
Total212121202020

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Morgan Stanley
Morgan Stanley
Hold
Maintains
$28 → $24
HoldMaintains$28 → $24+28.00%Nov 13, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
$31
BuyMaintains$31+65.33%Nov 11, 2026
BMO Capital
BMO Capital
Buy
Maintains
$34
BuyMaintains$34+81.33%Nov 10, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Reiterates
$36 → $38
BuyReiterates$36 → $38+102.67%Nov 6, 2026
Unknown Analyst
Leerink Partners
No rating
Leerink Partners
Buy
Maintains
$27
BuyMaintains$27+44.00%Nov 5, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.28B
from 1.07B
Increased by 19.52%
Revenue Next Year
1.45B
from 1.28B
Increased by 13.36%
EPS This Year
0.76
from 0.83
Decreased by -8.21%
EPS Next Year
1.08
from 0.76
Increased by 41.66%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
484.15M517.24M726.44M957.80M1.07B1.28B
Revenue Growth
9.60%6.83%40.45%31.85%11.87%19.52%
Operating Income
-170.44M-223.60M-73.38M84.28M104.81M149.87M
Net Income
-167.87M-215.98M-61.29M226.45M391.00M134.66M
EPS
----0.830.76
EPS Growth
-----38.99%-8.21%
Forward PE
--27.4035.9040.3824.62
Free Cash Flow
----105.15M358.90M
No. Analysts
-----19
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.3B
Avg1.3B
Low1.3B

Revenue Growth

Revenue Growth202620272028
High
20.5%
Avg
19.5%
Low
18.5%

EPS Forecast

EPS202620272028
High0.86
Avg0.76
Low0.59

EPS Growth

EPS Growth202620272028
High
3.6%
Avg
-8.2%
Low
-28.9%